Clinical Trial Update: Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetics study of NM6603 in Chinese patients with advanced solid tumors is being conducted and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• NM6603 (NM6603)

Snippet

Sponsor: NucMito Pharmaceuticals Co. Ltd. | Conditions: Cancers | Phase 1 | Status: RECRUITING